System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Antonio Costanzo is an expert in Dermatology at IRCCS Humanitas Research Hospital (Italy). As of October 2026, ScienceLeadR ranks Antonio Costanzo in the top 1% of experts worldwide for Psoriasis, Dermatitis and Skin Diseases, Papulosquamous. Antonio Costanzo has authored 549 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 16 of them ongoing. SLR score: 2,495 (community average: 125). How the SLR is computed.

LeadR Profile

Antonio Costanzo IRCCS Humanitas Research Hospital Italy
2 495 ScienceLeadR Reputation 2495

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Public Health - Immunology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026
Source: PubMed

IRCCS Humanitas Research Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 549

Citations

Citations: 16 098 1st author: 37 Last author: 92 Unique author: 1

Main journals

Dermatol Ther (Heidelb) 41
Br J Dermatol 39
J Dermatolog Treat 34
J Eur Acad Dermatol Venereol 31
Pharmeur Bio Sci Notes 25

Best Journals

J Clin Oncol 2
Lancet 2
Lancet Glob Health 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.
PMID 42839349 — sexually transmitted diseases, safety, eczema, dermatology		Acta Derm Venereol20260
Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study.
PMID 42823606 — safety, dermatitis, retrospective studies, therapeutics, janus kinase inhibitors, dermatitis, atopic		Dermatol Ther (Heidelb)20260
Response to methodological concerns in cumulative isotretinoin dose trials.
PMID 42706951 — isotretinoin, sexually transmitted diseases, skin diseases, contraceptives, oral, acne vulgaris		J Eur Acad Dermatol Venereol20260
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype.
PMID 42424135 — genes, rna editing, psoriasis, rna		J Exp Med20262
Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).
PMID 42663860 — abscess, quality of life, safety, pain, retrospective studies, hidradenitis suppurativa, drug-related side effects and adverse reactions, hidradenitis, therapeutics		Dermatol Ther (Heidelb)20261

Clinical Studies 37

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 21
Phase 2 4
Phase 4 4
N/A 3
Phase 2/Phase 3 3
Phase 1 1
Phase 3/Phase 4 1

By status:

Completed 17
Active not recruiting 9
Recruiting 7
Not yet recruiting 2
Terminated 1
Unknown 1

By type:

Interventional 35
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 2
multicentric5to9 0
multicentricup10 32

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

16 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase IB open label long term extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW LTE trial)
2024-511346-39-00 — immune system diseases, complement system proteins, complement pathway, classical		Phase 1Recruiting2025
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis
2024-520337-80-00 — safety		Phase 3Recruiting2026
A study to evaluate the long term safety tolerability and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00 — safety, hidradenitis suppurativa, hidradenitis		Phase 3Active not recruiting2025
Hidradenitis Suppurativa Evaluation of lutikizumab in Adult and Adolescent Subjects
2024-510730-40-00 — safety, hidradenitis suppurativa, signs and symptoms, hidradenitis, adolescent		Phase 3Active not recruiting2024
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in participants aged 12 years and older with moderate to severe atopic dermatitis
2023-508096-36-00 — injections, safety, dermatitis, maintenance, aged, therapeutics, injections, subcutaneous, dermatitis, atopic		Phase 3Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS